Clinical Trials Logo

Filter by:
NCT ID: NCT02515864 Completed - Healthy Clinical Trials

Clinical Pharmacology of FYU-981 (Effect on QT/QTc Interval)

Start date: August 2015
Phase: Phase 2
Study type: Interventional

A Placebo-controlled, Four Way Crossover Study to Investigate the Effect on QT/QTc Interval of a Single Dose of FYU-981, Compared with Placebo, Using Moxifloxacin as a Positive Control, in Healthy Male and Female Volunteers.

NCT ID: NCT02514603 Completed - Neoplasm Clinical Trials

A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers

Start date: October 2015
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.

NCT ID: NCT02513732 Completed - Clinical trials for Coronary Artery Disease

XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS)

Start date: July 2014
Phase:
Study type: Observational

The objective of the study is to evaluate the safety and efficacy of XIENCE Xpedition Everolimus-Eluting 2.25mm Stent in real world practice in Japanese hospitals.

NCT ID: NCT02513719 Completed - Clinical trials for Coronary Artery Disease

XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)

Start date: May 13, 2013
Phase:
Study type: Observational

The objective of the study is to evaluate the safety and efficacy of XIENCE PRIME SV in real world practice in Japanese hospitals.

NCT ID: NCT02513550 Completed - Plaque Psoriasis Clinical Trials

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

IXORA-P
Start date: August 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.

NCT ID: NCT02512068 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease

Start date: August 7, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of trelagliptin when administered at a dose of 25 mg once weekly using placebo as a control in patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal disease and inadequate glycemic control despite diet and/or exercise therapy (if given) or despite treatment with one antidiabetic drug in addition to diet and/or exercise therapy (if given); and to evaluate the long-term efficacy and safety of trelagliptin when administered at a dose of 25 mg once weekly to patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal disease.

NCT ID: NCT02510274 Completed - Clinical trials for Chronic Kidney Disease

Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan

Start date: May 12, 2014
Phase: Phase 1
Study type: Interventional

The objective of this study is to assess PK, safety and tolerability of a single oral dose of ASP3325 and to assess PD, PK and safety of repeated oral doses of ASP3325 administered t.i.d. before or just after each meal

NCT ID: NCT02510261 Completed - Amyloidosis Clinical Trials

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Start date: July 16, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).

NCT ID: NCT02509923 Completed - Healthy Clinical Trials

To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects

Start date: July 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate pharmacokinetics and pharmacodynamics of Z-215 (10 mg, 20 mg, 40 mg) , compared with Rabeprazole Sodium (10 mg, 20 mg ) in Healthy Male Subjects. And to evaluate food-effect in Healthy Male Subjects administrated Z-215 20 mg.

NCT ID: NCT02509039 Completed - Clinical trials for Lymphoma, Non-Hodgkin

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

Start date: September 2, 2015
Phase: Phase 1
Study type: Interventional

To determine the safety and tolerability of CC-122 when administered orally to adult Japanese subjects with advanced solid tumors or Non-Hodgkin's Lymphoma (NHL) and to define the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).